



Skin Solutions That Are More Than Skin Deep

Psoriasis is an immune-mediated skin condition that can cause rapid increases in skin cell production, leading to characteristic raised scaly patches.

Psoriasis can have a significant impact on measures of quality of life and often requires lifelong treatment.

Currently the mainstay of treatment for mild to moderate psoriasis is symptomatic management with topical therapies. More severe cases may require phototherapy and additional systemic treatments.

Consumers are increasingly taking an active interest in their own health and wellbeing. Symptom management is no longer left solely to the health professionals, with patients frequently seeking additional ways to manage their own symptoms.

Psoriasis affects approximately 100 million people worldwide¹

The World Health Organization reports that psoriasis can cause great physical, emotional and social burdens for patients¹

Nearly 60% of people with psoriasis reported their diagnosis to be a large problem in their everyday life²



Researchers have identified patterns in the microbiome of those with psoriasis—specifically an increase in *Akkermansia* species and a decrease in bacteria from the *Bacteroides* genus.³

Investigating the Gut Microbiome and its Role in Common Dermatological Conditions

Recent innovations in analytical techniques have allowed researchers to begin to understand the role of the gastrointestinal microbiome in skin conditions.

Alterations in the composition and diversity of the microorganisms that make up the gut microbiome have been linked to a number of conditions and diagnoses. Specifically this led to the identification of clear differences between the gut microbial composition of psoriasis patients and healthy people.

Recent findings have demonstrated the presence of bacterial DNA in blood samples of patients with psoriasis, indicating bacterial translocation from the intestinal lumen, something frequently associated with impaired epithelial barrier function.⁴

Microbiome research has shown that it is possible to affect outcomes in numerous diagnoses by modulating the microorganisms of the gut, and much research interest has been focused on the role of the microbiome in helping to understand and treat skin conditions.



ADM Probiotic Formulation Psoriasis: A Cutting-Edge Solution

ADM Probiotic Formulation Psoriasis is composed of 3 probiotic strains:

- *Bifidobacterium lactis* CECT 8145
- *Bifidobacterium longum* CECT 7347
- *Lactobacillus rhamnosus* CECT 8361

These bacterial strains have known anti-inflammatory effects, antioxidant activity and an ability to ameliorate the intestinal barrier. The psoriasis blend is supported with robust *in vitro* and pre-clinical evidence.

Clinical Evidence⁵

- A randomized double-blind, placebo-controlled clinical trial
- Women and men aged between 18 and 70 with mild or moderate plaque psoriasis were selected
- Intervention: the ADM Probiotic Formulation Psoriasis with a total of 1×10^9 colony-forming units (CFU) per capsule once daily for 12 weeks
- Two outcomes were evaluated to determine clinical response, Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA)

THE ADM PROBIOTIC FORMULATION PSORIASIS SHOWED CLINICAL RESULTS IN:

- Reducing psoriasis severity (PASI75) at 6 and 12 weeks
- Reducing the risk of relapse, over 6-month follow-up

The ADM Probiotic Formulation Psoriasis: A step forward in psoriasis management backed by science


IMPROVEMENTS IN PSORIASIS AREA AND SEVERITY INDEX (PASI)**:

66.7% of those taking the psoriasis blend showed a significant reduction in PASI index (75% or more improvement) compared to 41.9% in the control group after 12 weeks (p=0.0317).

- The decrease seen in the probiotic group was statistically significant when compared to placebo at 6 and 12 weeks.


**The Psoriasis Area Severity Index (PASI) is an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area into a single score in the range 0 (no disease) to 72 (maximal disease).

Percentage of patients with at least 75% reduction in PASI at 12 weeks



CHANGES IN PHYSICIAN GLOBAL ASSESSMENT (PGA):


A clinically relevant difference was observed in the Physician Global Assessment index: 48.9% in the probiotic group achieved a score 0 or 1, compared to 30.2% in the placebo group, although this difference was not statistically significant.



RISK OF RELAPSE:

80% of subjects from probiotic group remained symptom-free during the post study follow-up period compared to 58% in the control group. (p=0.027)

Percentage symptom-free after 6 months



MODULATION OF THE MICROBIOME:

Microbiome analysis showed that during the course of the trial a number of changes were noted, including increases in the proportion of lactobacilli and large reductions in *Micromonospora* and *Rhodococcus* genera. This modulation of the GI microbiome provides one potential explanation for the positive clinical outcomes seen in the probiotic group.

More Applications, More Benefits

Overall, the ADM Probiotic Formulation Psoriasis has been shown to have a beneficial effect as an adjunct therapy for the treatment of plaque psoriasis. ADM makes it easy for you to integrate Probiotic Formulation Psoriasis into any of your existing formulations. We'll not only support, but help you to create a science driven, innovative product within:



ADM Probiotic Formulation Psoriasis contains microorganisms originally collected from natural sources and is non-GMO. It comes in a powder format.

Ingredients:

3 probiotic strains:

Bifidobacterium lactis CECT 8145
Bifidobacterium longum CECT 7347
Lactobacillus rhamnosus CECT 8361

Maltodextrin
Sugar

Ingredients	Concentration	Format
<i>Bifidobacterium lactis</i> CECT 8145 <i>Bifidobacterium longum</i> CECT 7347 <i>Lactobacillus rhamnosus</i> CECT 8361	50B cfu/g 100B cfu/g	Powder
Maltodextrin Sugar		

CLAIMS AND CERTIFICATIONS

- EFSA QPS
- Non-GMO
- GRAS
- Organic Compliant
- Halal
- Gluten Free
- Kosher

SOURCES

- ¹ World Health Organization. (2016) Global Report on Psoriasis
- ² Stern, R.S., et al. (2004). *J Invest Dermatol Symp Proc.* 9(2): 136-9
- ³ Codoñer, F.M., et al. (2018) *Sci Rep.* 8: 3812
- ⁴ Ramírez-Boscá, A., et al. (2015) *JAMA Dermatol.* 151: 670-671
- ⁵ Navarro-López, V., et al. (2019) *Acta Derm Venereol.* 99: 1078-84

ADM DELIVERS FOR YOU

An innovative leader in the microbiome field, ADM delivers future-forward nutrition fueled by science, with a complete range of solutions from prebiotics, to probiotic and postbiotic strains, all clinically documented to deliver consumer benefits.

An expansive pantry of health & wellness ingredients including biotics, botanical extracts, vitamins, minerals and more means you can deliver innovative, science-driven supplements and food and beverage formulations to meet consumers' evolving functional nutrition needs. With our vertically integrated supply chain to ensure the reliability and availability of high-quality products and our dependable customer service, you get industry-leading quality solutions to ensure your success.

ARCHER DANIELS MIDLAND COMPANY DISCLAIMS ANY AND ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND SPECIFICALLY DISCLAIMS THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. OUR RESPONSIBILITY FOR ANY CLAIM IS LIMITED TO THE PURCHASE PRICE OF MATERIAL PURCHASED FROM US. CUSTOMERS ARE RESPONSIBLE FOR OBTAINING ANY LICENSES OR OTHER RIGHTS THAT MAY BE NECESSARY TO MAKE, USE, OR SELL PRODUCTS CONTAINING OUR INGREDIENTS. ANY CLAIMS MADE BY CUSTOMERS REGARDING INGREDIENT TRAITS MUST BE BASED ON THE SCIENTIFIC STANDARD AND REGULATORY/LEGISLATIVE REQUIREMENTS OF THE COUNTRY IN WHICH THE FINAL PRODUCTS ARE OFFERED FOR SALE.

©2021 Archer Daniels Midland Company

biopolis@adm.com | healthandwellness@adm.com
adm.com/yourwellness | biopolis.es

